Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Down 28.4% in February

Protara Therapeutics, Inc. (NASDAQ:TARA) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,970,000 shares, a drop of 28.4% from the February 13th total of 4,150,000 shares. Approximately 16.5% of the company’s stock are short sold. Based on an average daily trading volume, of 2,310,000 shares, the short-interest ratio is currently 1.3 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TARA. XTX Topco Ltd acquired a new position in Protara Therapeutics during the 3rd quarter worth $60,000. HBK Investments L P acquired a new position in Protara Therapeutics during the 4th quarter worth $106,000. Squarepoint Ops LLC acquired a new position in Protara Therapeutics during the 4th quarter worth $110,000. Dimensional Fund Advisors LP acquired a new position in Protara Therapeutics during the 4th quarter worth $111,000. Finally, Bailard Inc. acquired a new position in Protara Therapeutics during the 4th quarter worth $157,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Price Performance

Shares of TARA stock traded down $0.13 on Tuesday, hitting $4.29. The company’s stock had a trading volume of 57,086 shares, compared to its average volume of 784,673. Protara Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The firm’s fifty day moving average price is $4.39 and its 200-day moving average price is $3.51. The stock has a market capitalization of $88.50 million, a price-to-earnings ratio of -1.52 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. Analysts predict that Protara Therapeutics will post -3.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TARA has been the subject of a number of research reports. Guggenheim reissued a “buy” rating and set a $20.00 target price on shares of Protara Therapeutics in a research note on Friday, December 6th. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They set an “outperform” rating and a $22.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a research note on Friday. They issued an “overweight” rating for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Protara Therapeutics presently has an average rating of “Buy” and a consensus target price of $22.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.